A Northwestern Medicine study has uncovered a promising new therapeutic approach for a rare genetic brain disorder, according ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% reduction in progression or death. The MajesTEC-9 trial highlights ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

Russell has a PhD in the history of medicine, violence, and colonialism. His research has explored topics including ethics, science governance, and medical involvement in violent contexts. Russell has ...

Two novel sub-types of multiple sclerosis (MS) have been identified, a discovery potentially paving the way for new treatments. Researchers employed artificial intelligence (AI) to assess brain scans ...

A study from Sweden’s Uppsala University discovered a link between microplastics and multiple sclerosis (MS). The research, published in the journal Environmental International, discovered that ...

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...

Lipoic acid showed mixed results in a new clinical trial The supplement slowed loss of gray matter in patients with progressive MS However, it did not improve their walking speed WEDNESDAY, Dec. 17, ...

Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...

Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...

In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...

Please provide your email address to receive an email when new articles are posted on . At week 96, treatment led to significant reductions in all exploratory MS-related biomarkers. Additional ...